Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study.
Maria PappaMaria KosmetatouAntigone PietaMyrto NikoloudakiNektarios Marios LiapisChristina TsalapakiAglaia ChalkiaEvangelia ArgyriouTheodoros DimitroulasMyrto CheilaGeorgios DemirtzoglouCharalampos PapagorasAndreas GoulesChristina KatsiariDimitrios VassilopoulosProdromos SidiropoulosKyriaki A BokiPetros P SfikakisGeorge LiapisHarikleia GakiopoulouParaskevi Vasileios VoulgariDimitrios T BoumpasGeorge K BertsiasMaria G G TektonidouAntonis FanouriakisPublished in: RMD open (2024)
More than two-thirds of patients with LN attain EULAR/ERA-EDTA response rates by 12 months, but 20% require therapy modifications within this time period. Patients with increased chronicity in baseline biopsy, when combined with histological activity, are at higher risk for a lack of clinical response.